Spectruth DAO’s Proprietary Synthetic Ibogaine Process Patent: Pioneering Sustainable Solutions for Trauma Healing

Spectruth DAO has developed and patented a revolutionary synthetic ibogaine production process that addresses critical challenges in the natural sourcing of ibogaine—a promising psychedelic alkaloid with significant therapeutic potential for treating PTSD and trauma-related disorders. Our proprietary, scalable synthesis leverages cutting-edge biocatalytic and chemical cascade methodologies to produce high-purity, pharmaceutical-grade ibogaine in an environmentally sustainable and cost-effective manner.

This innovative process utilizes enzymatic conversion of sustainable plant biomass precursors followed by optimized chemical reactions and rigorous purification protocols that ensure over 99% ibogaine purity. Spectruth DAO’s approach eliminates reliance on natural plant extraction, overcoming supply chain, sustainability, and regulatory constraints that have historically limited ibogaine’s clinical development and access.

Our synthesis aligns with breakthrough academic research from top institutions including Stanford University and the University of California Davis, who have demonstrated modular and efficient total synthesis strategies. These scientific foundations enable Spectruth DAO to lead the market toward scalable production and commercialization of synthetic ibogaine for neurotherapeutic applications.